Since Glp-1R agonists or analogues have not been tested in diabetic subjects with gastric or duodenal ulcers, the results of this study may provide fundamental evidence for the subsequent comparative studies between different antipeptic ulcer therapies in diabetes. Here, GLP1R is linked to duodenal ulcer.